Kaposi’s sarcoma (KS) is a neoplastic disease of endothelial cells, which accounts for some 3% of organ transplantation malignancies, and it is also common in HIV infection. KS incidence seems increased with Cyclosporine (CSA) therapy, as compared with conventional immunosuppression (1, 2). In our unit, 4 out of 150 CSA-treated recipients developed KS, while no other malignancies have been recorded. This occurred despite a low-dose CSA regimen (3), as compared with the absence of neoplasia in other 150 patients receiving conventional treatment.The clinical features of our KS cases were reviewed.
